In a recent clinical study update, AstraZeneca has completed a Phase 2a study titled ‘A Phase 2a Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice ...
You’d think that New York Rangers coach Mike Sullivan has zero interest in messing with a good thing after their first home win of the season Monday night at Madison Square Garden. Whether the Rangers ...
The population assigned to the centres was mostly urban, of medium-low socioeconomic level. Patients who sought care and initiated treatment with a fixed-dose ICS/LABA combination between 1 January ...
Chronic obstructive pulmonary disease (COPD) treatments involving inhaled corticosteroids (ICSs) were associated with a greater risk for fractures, a meta-analysis of several dozen randomized trials ...
Surveys of more than 1,000 Italian patients and clinicians uncover why oral steroid use remains widespread in asthma care, revealing gaps in guideline adherence, patient education, and access to ...
AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the closing of a $21 ...
Preferred treatment options for uncontrolled asthma in people on medium-dose inhaled corticosteroids
• Adding a long-acting beta2-agonist (LABA) or a long-acting muscarinic antagonist (LAMA) to medium-dose inhaled corticosteroids (ICS) likely reduces asthma attacks requiring treatment with oral ...
Patients with severe asthma are most often referred to consultants for their persistent oral corticosteroids requirements, recurrent exacerbations and debilitating symptoms. It has been our experience ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...
On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...
Results showed budesonide/glycopyrronium/formoterol fumarate 320/28.8/9.6μg met all primary endpoints in both KALOS and LOGOS. Topline data were announced from two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback